Aim:

- “Comparative Study of Safety and Efficacy of Fixed Dose Combination of Metformin and Voglibose Versus Fixed Dose Combination of Metformin and Pioglitazone on HOMA-IR, HbA1c and Lipid Levels in prediabetes patients”

Objectives:

- To evaluate the effect of FDC of Metformin and Voglibose on Serum Insulin and HOMA-IR in Prediabetes Patients.

- To evaluate the effect of FDC of Metformin and Pioglitazone on Serum Insulin and HOMA-IR in Prediabetes Patients.

- To compare effect of FDC of Metformin and Voglibose versus FDC of Metformin Pioglitazone and on Serum Insulin and HOMA-IR in Prediabetes Patients.

- To evaluate the effect of FDC of Metformin and Voglibose combination on FBS, PPBS, HbA1c in Prediabetes Patients.

- To evaluate the effect of FDC of Metformin and Pioglitazone combination on FBS, PPBS, HbA1c in Prediabetes Patients.

- To compare effect of FDC of Metformin and Voglibose versus FDC of Metformin and Pioglitazone on FBS, PPBS, HbA1c in Prediabetes Patients.

- To evaluate the effect of FDC of Metformin and Voglibose on lipid levels (Total Cholesterol, Serum Triglycerides, HDL, LDL, VLDL) in Prediabetes.

- To evaluate the effect of FDC of Metformin and Pioglitazone on lipid levels in Prediabetes.

- To compare effect of FDC of Metformin and Voglibose versus FDC of Metformin and Pioglitazone on lipid levels in Prediabetes.
- To evaluate the safety of FDC of Metformin and Voglibose combination in Prediabetes Patients as per adverse effects reported by patients.

- To evaluate the safety of FDC of Metformin and Pioglitazone combination in Prediabetes Patients as per adverse effects reported by patients.